Shire

Shire, founded in 1986, is a globally leading biotechnology company. In its early days, Shire launched a series of calcium supplements targeting patients in need of prevention and treatment for osteoporosis. In the mid-1990s, Shire began a series of strategic acquisitions to expand into new businesses, develop new products, and bring them to market. Over the following two decades, Shire experienced continuous growth and strong momentum. After acquiring Baxalta in 2016, the company added three therapeutic areas—hematology, immunology, and oncology—further strengthening its capabilities to become a global leader in biotechnology. Since then, Shire has focused on serving patients with rare diseases.